The Alopecia Areata market report also offers comprehensive insights into the Alopecia Areata market size, share, Alopecia Areata epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Alopecia Areata market size growth forward.
Some of the key highlights from the Alopecia Areata Market Insights Report:
-
Several key pharmaceutical companies, including Pfizer, Legacy Healthcare, Horizon Therapeutics, Concert Pharmaceuticals, Reistone Biopharma, and others, are developing novel products to improve the Alopecia Areata treatment outlook.
-
In July 2024, the FDA approved Sun Pharmaceutical’s oral Janus kinase (JAK) inhibitor, Leqselvi (deuruxolitinib), for the treatment of severe alopecia areata in adult patients.
-
In February 2024, Pelage Pharmaceuticals revealed it had secured funding to initiate phase 2 trials of PP405, a novel topical treatment for androgenetic alopecia and other types of hair loss. PP405 is a non-invasive, small molecule designed to inhibit the mitochondrial pyruvate carrier (MPC), reactivating dormant hair follicle stem cells to stimulate hair growth.
-
DelveInsight estimates that in 2023, around 1.7 million people were diagnosed with alopecia areata across the 7MM. The United States represented 35% of these cases, while EU4 and the UK accounted for nearly 49%, and Japan made up 16%.
-
The alopecia areata market is expected to experience steady growth, with a strong compound annual growth rate (CAGR) forecasted from 2024 to 2034. This growth across the 7MM will be fueled by the introduction of innovative treatments like RINVOQ (upadacitinib), coacillium (LH-8), bempikibart, and Rezpegaldesleukin (NKTR-358), among others.
-
DelveInsight’s analysis also suggests that the alopecia market in the 7MM was valued at approximately USD 379 million in 2023. From 2024 to 2034, the market is projected to grow at a CAGR of 21.2%.
-
Key players in the alopecia market, including Eli Lilly and Company, Incyte Corporation, Pfizer, and Sun Pharmaceuticals, are offering approved treatments such as OLUMIANT (in the US, EU, and Japan), LITFULO (in the US, EU, and Japan), and LEQSELVI (in the US).
-
There is a rising demand for safer and more effective treatments, which presents opportunities for the development of therapies that can achieve remission without requiring long-term use or posing risks like black box warnings. The introduction of new therapies could intensify competition and reduce the market share of established treatments like LITFULO and OLUMIANT, as more options become available to meet the needs of patients and healthcare providers.
-
As per DelveInsight analysis, the Alopecia Areata market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Alopecia Areata Market Landscape
Alopecia Areata Overview
Alopecia areata is a common autoimmune skin disorder that causes hair loss on the scalp, face, and sometimes other parts of the body. It affects people of all ages, genders, and ethnicities, making it a broadly impactful condition.
The disorder manifests in several forms, with the main types being patchy alopecia areata, alopecia totalis, and alopecia universalis. Other clinical variants include persistent patchy, diffuse, and ophiasis alopecia areata. It is classified as a “polygenic disease” due to its genetic basis and multifactorial inheritance.
Alopecia areata is an autoimmune disorder that targets hair follicles, leading to sudden hair loss, typically in small patches that can expand into larger bald areas. The condition can also affect other regions, such as the eyelashes, eyebrows, or beard (in men), and typically occurs without redness, rashes, or scarring on the affected skin.
Several factors contribute to alopecia areata, including nutritional deficiencies, systemic diseases like autoimmune or thyroid disorders, and stress, which can disrupt immune function. Genetic predisposition, environmental factors such as infections or allergens, and certain medications can also play a role, with a family history often increasing the likelihood of developing the condition.
Do you know the treatment paradigms for different countries? Download our Alopecia Areata Market Sample Report
Alopecia Areata Epidemiology Insights
-
In 2023, the United States had the largest number of prevalent alopecia areata cases, with around 764 thousand cases. This figure is projected to rise by 2034, growing at a compound annual growth rate (CAGR) of 1.4%.
Alopecia Areata Epidemiology Segmentation
DelveInsight’s Alopecia Areata market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Alopecia Areata historical patient pools and forecasted Alopecia Areata patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Alopecia Areata Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
-
Alopecia Areata Prevalence
-
Age-Specific Alopecia Areata Prevalence
-
Gender-Specific Alopecia Areata Prevalence
-
Diagnosed and Treatable Cases of Alopecia Areata
Visit for more @ Alopecia Areata Epidemiological Insights
Alopecia Areata Market Outlook
Alopecia areata is a chronic autoimmune disorder that leads to non-scarring hair loss, often starting as patchy bald spots on the scalp but potentially spreading to other hair-covered areas. The immune system attacks hair follicles, disrupting the natural growth cycles. The condition can range from localized patches to complete hair loss (alopecia totalis or universalis). Both genetic and environmental factors play a role in its development. In addition to its physical effects, alopecia areata has a significant impact on emotional well-being and quality of life.
The treatment approach for alopecia areata has evolved to include a combination of medications and supportive care. The market offers various therapies, such as corticosteroids, immunosuppressants, immunomodulators, and topical sensitizers or irritants. Corticosteroids are central due to their anti-inflammatory effects, reducing immune attacks on hair follicles, while immunosuppressants and immunomodulators are used for more severe or resistant cases to help regulate the immune system and prevent further hair loss.
Topical sensitization treatments, such as diphencyprone, induce a mild allergic reaction to shift the immune response away from hair follicles. Similarly, topical irritants are used to provoke irritation and stimulate hair regrowth. Minoxidil, a vasodilator, increases blood flow to hair follicles and is often used off-label for alopecia areata. Dithranol, which is less commonly used, creates controlled inflammation to alter immune responses and encourage hair regrowth, mainly in cases of patchy alopecia areata as part of sensitization therapy.
Several drugs have been approved for the treatment of alopecia areata, highlighting the focus on immune modulation therapies. Notable options include OLUMIANT, a small molecule co-developed by Eli Lilly and Incyte Corporation, LITFULO, a JAK3 and TEC kinase inhibitor from Pfizer, and LEQSELVI, a JAK1 and JAK2 inhibitor developed by Sun Pharmaceuticals.
Alopecia Areata Marketed Drugs
-
OLUMIANT (Baricitinib): Eli Lilly and Company/Incyte Corporation
-
LITFULO (Ritlecitinib): Pfizer
-
LEQSELVI (Deuruxolitinib, CTP 543): Sun Pharmaceuticals
Alopecia Areata Emerging Drugs
-
RINVOQ (Upadacitinib): AbbVie
-
Bempikibart (ADX-914): Q32 Bio
-
Amlitelimab (SAR-445229): Sanofi
Alopecia Areata Key Companies
-
Pfizer, Legacy Healthcare, Horizon Therapeutics, Concert Pharmaceuticals, Reistone Biopharma, and others
For more information, visit Alopecia Areata Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Alopecia Areata Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Alopecia Areata, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Alopecia Areata epidemiology in the 7MM
-
Alopecia Areata marketed and emerging therapies
-
Alopecia Areata companies
-
Alopecia Areata market drivers and barriers
Table of Contents:
1 Alopecia Areata Market Key Comprehensive Insights
2 Alopecia Areata Market Report Introduction
3 Competitive Intelligence Analysis for Alopecia Areata
4 Alopecia Areata Market Analysis Overview at a Glance
5 Executive Summary of Alopecia Areata
6 Alopecia Areata Epidemiology and Market Methodology
7 Alopecia Areata Epidemiology and Patient Population
8 Alopecia Areata Patient Journey
9 Alopecia Areata Treatment Algorithm, Alopecia Areata Current Treatment, and Medical Practices
10 Key Endpoints in Alopecia Areata Clinical Trials
11 Alopecia Areata Marketed Therapies
12 Alopecia Areata Emerging Therapies
13 Alopecia Areata: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Alopecia Areata
16 Alopecia Areata Market Key Opinion Leaders Reviews
18 Alopecia Areata Market Drivers
19 Alopecia Areata Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Alopecia Areata Epidemiology 2034
DelveInsight’s “Alopecia Areata – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Alopecia Areata epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Alopecia Areata Pipeline 2024
“Alopecia Areata Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Alopecia Areata market. A detailed picture of the Alopecia Areata pipeline landscape is provided, which includes the disease overview and Alopecia Areata treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/